Waltham, MA, United States of America

Yun Ding

USPTO Granted Patents = 4 


 

Average Co-Inventor Count = 3.3

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2011-2012

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Yun Ding - Innovating Therapies with sEH Inhibitors

Introduction:

In the realm of pharmaceutical innovations, Yun Ding, based in Waltham, MA (US), has made significant contributions with his expertise in the development of sEH inhibitors. With four patents to his name, Ding has demonstrated a commitment to advancing treatments for diseases mediated by the soluble epoxide hydrolase (sEH) enzyme.

Latest Patents:

Yun Ding's latest patents focus on the novel sEH inhibitors and their potential therapeutic applications. The first patent centers around the compound (Cis)-N-{[4-cyano-2-(trifluoromethyl)phenyl]methyl}-3-{[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino}cyclohexanecarboxamide and a pharmaceutically acceptable salt thereof. The second patent expands on this concept, presenting compounds according to Formula I, including R1, R2, R4, R5, R6, A, B, Y, Z, n, and m, as defined within. These sEH inhibitors exhibit potential in the treatment of diseases such as hypertension.

Career Highlights:

Yun Ding has made remarkable strides in his tenure at GlaxoSmithKline LLC, a renowned pharmaceutical company dedicated to developing innovative therapies. Leveraging his expertise in sEH inhibitors, Ding has contributed significantly to the company's research and development efforts, helping to advance novel treatments for diseases mediated by the sEH enzyme.

Collaborations:

Throughout his career, Yun Ding has collaborated with esteemed professionals in the field. Notably, he has worked alongside Joseph P. Marino Jr and Reema K. Thalji, who have also contributed their expertise and insights to the development of sEH inhibitors.

Conclusion:

Yun Ding's patented work in sEH inhibitors demonstrates his profound commitment to catalyzing advancements in healthcare. His diligent efforts at GlaxoSmithKline LLC have contributed to the development of innovative therapies for diseases mediated by the sEH enzyme. With his continued dedication to scientific research, Yun Ding is poised to make even greater contributions to the field of pharmaceutical innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…